Compare ONCY & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONCY | STIM |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.5M | 95.6M |
| IPO Year | 2002 | 2018 |
| Metric | ONCY | STIM |
|---|---|---|
| Price | $0.88 | $1.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $7.33 | $3.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $52,776,000.00 |
| Revenue This Year | N/A | $11.10 |
| Revenue Next Year | $2,505.00 | $11.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.80 |
| 52 Week High | $1.51 | $4.84 |
| Indicator | ONCY | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 58.99 |
| Support Level | $0.82 | $1.23 |
| Resistance Level | $1.14 | $1.80 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 10.17 | 87.88 |
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.